Novo Nordisk shares have dropped significantly in December due to disappointing CagriSema trial results, but not everything from those results was negative. Amycretin's promising early-stage ...

The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo's targeted expectation of at least 25% weight loss. The press release ...

The Novo Nordisk class action lawsuit further alleges that on December 20, 2024, defendants published headline results from their REDEFINE-1 CagriSema obesity trial, disclosing that "[t]he REDEFINE 1 ...

The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo’s targeted expectation of at least 25% weight loss. The press release ...

Despite a recent decline following disappointing trial results for its new weight-loss drug, CagriSema, and weaker-than-expected third-quarter sales, the company continues to post strong growth.

The Allegations: Robbins LLP is Investigating Allegations that Novo Nordisk A/S (NVO) Misled Investors Regarding REDEFINE-1, Novo’s Phase 3 CagriSema Study on Obesity According to the complaint ...

The adjustment follows Novo Nordisk's management providing more insight into the role of their next-generation obesity product, CagriSema, in the company's portfolio. Despite CagriSema's less-than ...

In December, the company lost more than $70B in market cap in a single day after announcing that its next-gen obesity candidate, CagriSema, caused only ~20% of weight loss in a Phase 3 trial ...

Despite a recent decline following disappointing trial results for its new weight-loss drug, CagriSema, and weaker-than-expected third-quarter sales, the company continues to post strong growth. Novo ...

A copy of the Complaint can be obtained at www.pomerantzlaw.com. On December 20, 2024, Novo announced headline results for its REDEFINE-1 trial, which determined that the Company's CagriSema product ...